Mercado Global de Tratamento da Dengue – Tendências do Setor e Previsão para 2031

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado Global de Tratamento da Dengue – Tendências do Setor e Previsão para 2031

  • Pharmaceutical
  • Publish Reports
  • Jun 2024
  • Global
  • 350 Páginas
  • Número de tabelas: 649
  • Número de figuras: 57

Global Dengue Treatment Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Diagram Período de previsão
2024 –2031
Diagram Tamanho do mercado (ano base )
USD 878.54 Million
Diagram Tamanho do mercado ( Ano de previsão)
USD 2,121.43 Million
Diagram CAGR
%
Diagram Principais participantes do mercado
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
  • Johnson & Johnson Services
  • Inc.

>Mercado global de tratamento da dengue, por estirpes (DENV-2, DENV-3, DENV-1, DENV-4 e outras), tipo (vacinas e paracetamol), gravidade (dengue ligeira a moderada e dengue grave), via de administração ( Parentérica e Oral), Modo de Compra (Prescrição e Venda Livre (OTC)), Sexo (Masculino e Feminino), Idade (Adulto, Pediátrico e Geriátrico), Utilizador Final (Hospital, Clínicas Especializadas, Assistência Médica Domiciliária e Outros), Canal de Distribuição (Farmácias de Retalho, Farmácias Hospitalares e Farmácias Online) - Tendências e Previsões do Sector para 2031.

Mercado de Tratamento da Dengue

Análise e dimensão do mercado de tratamento da dengue

Os fatores impulsionadores responsáveis ​​pelo crescimento do mercado global de tratamento da dengue são a crescente aplicação do tratamento da dengue na indústria médica e farmacêutica, o aumento contínuo dos lançamentos de vacinas, à medida que alarga o arsenal de ferramentas disponíveis para os profissionais de saúde , e autoridades de saúde pública. No entanto, uma restrição significativa para o mercado são os efeitos secundários relacionados com o tratamento da dengue.

Mercado de Tratamento da DengueMercado de Tratamento da Dengue

A Data Bridge Market Research analisa que o mercado global de tratamento da dengue deverá atingir os 2.121,43 milhões de dólares até 2031, face aos 878,54 milhões de dólares em 2023, crescendo a um CAGR de 11,6% no período previsto de 2024 a 2031.

Métrica de reporte

Detalhes

Período de previsão

2024 a 2031

Ano base

2023

Anos históricos

2022 (personalizável para 2016-2021)

Unidades Quantitativas

Receita em milhões de dólares

Segmentos cobertos

Estirpes (DENV-2, DENV-3, DENV-1, DENV-4 e outros), tipo ( vacinas e paracetamol), gravidade (dengue ligeira a moderada e dengue grave), via de administração (parenteral e oral), modo de Compra (Prescrição e Isento de Prescrição (OTC)), Sexo (Masculino e Feminino), Idade (Adulto, Pediátrico e Geriátrico), Utilizador Final (Hospital, Clínicas Especializadas, Assistência Médica Domiciliária e Outros), Canal de Distribuição ( Farmácias de Retalho , farmácias hospitalares e farmácias on-line)

País coberto

 EUA, Canadá, México, Alemanha, Reino Unido, Itália, França, Espanha, Rússia, Suíça, Turquia, Bélgica, Holanda, Resto da Europa, Japão, China, Coreia do Sul, Índia, Singapura, Tailândia, Indonésia, Malásia, Filipinas , Austrália , Resto da Ásia-Pacífico, Brasil, Argentina, Resto da América do Sul, África do Sul, Egito, Arábia Saudita, Emirados Árabes Unidos, Israel e Resto do Médio Oriente e África

Participantes do mercado abrangidos

Sanofi, Takeda Pharmaceutical Company Limited, Viatris Inc., Johnson & Johnson Services, Inc., GSK plc., Perrigo Company PLC, Baxter, Fresenius Kabi USA, Pfizer, Hikma Pharmaceuticals Plc, SUN PHARMACEUTICAL INDUSTRIES LTD, Teva Pharmaceuticals USA, Inc. e Aurobindo Pharma, entre outros

Definição de mercado

Dengue is a viral disease transmitted by mosquitoes which has spread rapidly in all WHO regions in recent years. The dengue virus is mainly transmitted by female mosquitoes from the genus Aedes aegypti and to a lesser degree, from Aedes albopictus. The diseases transmitted by these vector mosquitoes are Chikungunya, yellow fever and Zika viruses. Dengue is prevalent in the tropical geographic regions, induced by precipitation, temperature, relative humidity and unplanned rapid urbanization with local risk variability.

Global Dengue Treatment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

  •  Rising Dengue Incidence Rate Results in the Demand for Effective Treatment

The global increase in the incidence rate of dengue is a significant driver for the dengue treatment market. Dengue fever, caused by the dengue virus and transmitted by Aedes mosquitoes, has seen a dramatic rise in cases worldwide, particularly in tropical and subtropical regions. This surge is attributed to factors such as urbanization, climate change, and increased travel, which facilitate the spread of both the virus and its mosquito vectors. As the number of affected individuals grows, the demand for effective treatments and preventive measures intensifies. This has led to increased investment in research and development of antiviral drugs, vaccines, and supportive care options. Pharmaceutical companies and research institutions are intensifying their efforts to develop vaccines and innovative treatments to combat this pervasive disease. The high incidence rate, coupled with the potential for severe health complications and economic impact, is propelling investments and advancements in the dengue treatment market, aiming to mitigate the widespread and recurrent threat of dengue fever.

  •  Rising Wave of Dengue Vaccine Launches

The rise of dengue vaccine launches marks as an important factor in the fight against this mosquito-borne disease. With increasing awareness of the global burden of dengue and the pressing need for effective prevention strategies, pharmaceutical companies are stepping up their efforts to develop and introduce vaccines. This surge in vaccine launches serves as a significant driver for market growth, as it expands the arsenal of tools available to healthcare professionals and public health authorities. As more vaccines enter the market, competition intensifies, leading to innovation and improved formulations aimed at enhancing efficacy and safety. As a result, the dengue vaccine market is witnessing robust growth, with projections indicating sustained expansion in market share and revenue for key players in the years to come.

Mercado de Tratamento da Dengue

Opportunity

  • Growing Number of Pipeline Vaccines for Dengue Treatment

The increasing number of pipeline vaccines for dengue treatment can enhance significant opportunities for market growth. With multiple candidates in development, there's potential for improved efficacy, safety, and coverage across diverse demographics and geographic regions. This aspect encourage healthy competition among developers, driving innovation and pushing for more cost-effective solutions. As dengue fever remains a global health concern, particularly in tropical and subtropical regions, the availability of more vaccines can help meet growing demand. The expanding pipeline of dengue vaccines not only addresses a critical public health need but also offers promising prospects for market growth through enhanced product offerings and increased opportunities for the pharmaceutical manufacturer.

Restraints/Challenges

  • Healthcare Services are Limitedly Accessible in Rural Areas

Limited access to healthcare services in dengue treatment poses significant challenges for the market, primarily by reducing the patient pool and hindering timely diagnosis and treatment. With fewer patients seeking medical attention promptly, there's a risk of increased disease burden, leading to more severe cases and higher healthcare costs. Limited access exacerbates the strain on healthcare systems and resources in affected regions, potentially impacting the availability and affordability of dengue treatments. These rural regions lack well-equipped medical facilities and specialized services, making it difficult for residents to access timely and quality care. Rugged terrain and long distances to healthcare facilities exacerbate the problem, especially where transportation networks are inadequate. Overall, addressing barriers to healthcare access is crucial for effectively managing dengue and sustaining market growth in this sectorSafety concerns related to dengue treatment are a significant challenge, particularly given its widespread use in cosmetic and medical applications. While Dengue Treatment is generally considered safe and is naturally present in the human body, potential risks arise from its synthetic or extracted forms used in dermal fillers and other treatments. Adverse reactions can include allergic responses, infections, and granuloma formation, particularly if the substance is not properly purified or administered. Additionally, improper injection techniques can lead to complications such as vascular occlusion, which can cause tissue necrosis and, in severe cases, blindness. Ensuring the safety of Dengue Treatment products thus requires stringent quality control, thorough clinical testing, and professional administration by qualified healthcare providers.

  • Delay in the Approval Process of Vaccines

The delay in the approval process of dengue vaccines presents a significant restraint on the market's growth, posing multifaceted challenges to both vaccine developers and public health initiatives. Regulatory hurdles, stringent efficacy and safety requirements, and complex trial protocols contribute to prolonged timelines from vaccine development to market availability. These delays hinder the timely availability of vaccines, affecting public health outcomes and prolonging the duration of disease outbreaks. Moreover, prolonged approval timelines can deter investment in vaccine research and development, as companies may perceive a higher risk of uncertainty and reduced profitability. Furthermore, the protracted approval process undermines investor confidence, as prolonged development cycles increase financial risks and uncertainty regarding return on investment. Moreover, the delayed availability of dengue vaccines perpetuates the reliance on traditional preventive measures, such as vector control and symptomatic treatment, which may not offer comprehensive protection against the disease. This prolongs the burden on healthcare infrastructure, leading to increased healthcare costs and strain on resources in endemic regions.

Recent Developments

  • In May 2024, Johnson & Johnson (JNJ) revealed its definitive agreement to acquire Yellow Jersey Therapeutics (YJT), a wholly-owned subsidiary of Numab therapeutics, in an all-cash transaction valued at around USD1.25 billion. This strategic acquisition is poised to bolster JNJ's growth trajectory by expanding its portfolio in the biopharmaceutical sector. By integrating YJT's innovative pipeline and expertise, JNJ aims to enhance its capabilities in developing novel therapies, ultimately strengthening its position as a leader in the healthcare industry
  • In August 2023, according to the article by the FDA, DENGVAXIA, a tetravalent live vaccine manufactured by Sanofi Pasteur, Inc., is indicated for the prevention of dengue disease caused by serotypes 1, 2, 3, and 4 of the dengue viruses. Approved for individuals aged 6 through 16 years, it is specifically targeted at those residing in endemic areas who have a laboratory-confirmed previous dengue infection. This vaccine represents a significant advancement in combatting dengue fever, offering targeted protection against multiple serotypes of the virus, thereby potentially reducing the incidence rate of dengue infections in vulnerable populations
  • In February 2024, according to the article by Takeda Pharmaceutical Company Limited., the company committed to producing up to 50 million doses annually of QDENGA, the Dengue Tetravalent Vaccine (Live, Attenuated), accelerating Takeda's goal of delivering 100 million doses per year by 2030. These multi-dose vials (MDVs) are designated to aid in government procurement for National Immunization Programs in endemic countries by 2030, facilitating broader access to dengue vaccination and contributing to global disease prevention efforts. Additionally, two live-attenuated dengue vaccines are in phase 3 developments which are, the TDV developed by Takeda and the LAV Delta 30 developed by NIH/Butantan Institute
  • In July 2019, Hikma Pharmaceuticals Inc. and Civica Rx signed long-term agreement to minimize the future generic drug shortages in the US region this will help the company to expand their generics sales and to build a customer base which will increase the net revenue and sales
  • In Novemeber 2019, Perrigo Company plc announced that their “Quitting is Better” therapy campaign has won a notable national award for the Best OTC Corporate Social Responsibility Campaign. The company won for innovation and strategic marketing by a panel of volunteer judges comprised of industry representatives that are members of the Consumer Healthcare Products Association (CHPA). This will increase the company profile in the global region

Global Dengue Treatment market Scope

The global dengue treatment market is segmented into nine notable segments which are based on the strains, type, severity, route of administration, mode of purchase, gender, age, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Strains

  • DENV-2
  • DENV-3
  • DENV-1
  • DENV-4
  • Others

On the basis of strains, the market is segmented into DENV-2, DENV-3, DENV-1, DENV-4, and others.

Type

On the basis of type, the market is segmented into vaccines and acetaminophen.

Severity

  • Mild to Moderate Dengue
  • Severe Dengue

On the basis of severity, the market is segmented into mild to moderate dengue and severe dengue.

Route of Administration

  • Parenteral
  • Oral

On the basis of route of administration, the market is segmented into parenteral and oral.

Mode of Purchase

  • Prescription
  • Over-the-Counter (OTC)

On the basis of mode of purchase, the market is segmented into prescription and over-the-counter (OTC).

Gender

  • Male
  • Female

On the basis of gender, the market is segmented into male and female.

Age

  • Adult
  • Pediatric
  • Geriatric

On the basis of age, the market is segmented into adult, pediatric, and geriatric.

End User

  • Hospital
  • Specialty Clinics
  • Home Healthcare
  • Others

On the basis of end user, the market is segmented into hospital, specialty clinics, home healthcare, and others.

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

On the basis of distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.

Mercado de Tratamento da Dengue

Global Dengue Treatment Market Regional Analysis/Insights

The global dengue treatment market is analyzed and market size insights and trends are provided by strains, type, severity, route of administration, mode of purchase, gender, age, end user, and distribution channel.

The countries covered in the global dengue treatment market are U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa.

Asia-Pacific is expected to dominate the global dengue treatment market due to growth of medical insurance in the region. India is expected to dominate the Asia-Pacific dengue treatment market due to rising wave of dengue vaccine launches in the country. France is expected to dominate the Europe dengue treatment market due to government initiatives and vaccination programs in the country. Brazil is expected to dominate the South America dengue treatment market due to rising dengue incidence rate in the country.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Mercado de Tratamento da Dengue

Competitive Landscape and Global Dengue Treatment Market Share Analysis

The global dengue treatment competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, company strengths and weaknesses, product launch, product approvals, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.

Some of the major market players operating in this market are Sanofi, Takeda Pharmaceutical Company Limited, Viatris Inc., Johnson & Johnson Services, Inc., GSK plc., Perrigo Company PLC, Baxter, Fresenius Kabi USA, Pfizer, Hikma Pharmaceuticals Plc, SUN PHARMACEUTICAL INDUSTRIES LTD, Teva Pharmaceuticals USA, Inc., and Aurobindo Pharma among others.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL DENGUE TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 GLOBAL DENGUE TREATMENT MARKET: REGULATIONS

5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT

5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT

5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK

5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE

5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT

6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES

6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS

6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES

6.2 RESTRAINTS

6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES

6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE

6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE

6.3 OPPORTUNITIES

6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET

6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT

6.3.3 RISING R&D INVESTMENT AND ACTIVITIES

6.4 CHALLENGES

6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS

6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS

7 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS

7.1 OVERVIEW

7.2 DENV-2

7.3 DENV-3

7.4 DENV-1

7.5 DENV-4

7.6 OTHERS

8 GLOBAL DENGUE TREATMENT MARKET, BY TYPE

8.1 OVERVIEW

8.2 VACCINES

8.2.1 DENGVAXIA (CYD-TDV)

8.2.2 QDENGA

8.3 ACETAMINOPHEN

8.3.1 PARENTERAL

8.3.2 ORAL

8.3.3 OTHER

9 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY

9.1 OVERVIEW

9.2 MILD TO MODERATE DENGUE

9.3 SEVERE DENGUE

10 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 PARENTERAL

10.2.1 SUB-CUTANEOUS

10.2.2 INTRAVENOUS

10.3 ORAL

10.3.1 TABLET

10.3.2 CAPSULES

10.3.3 OTHERS

11 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE

11.1 OVERVIEW

11.2 PRESCRIPTION

11.3 OVER-THE-COUNTER (OTC)

12 GLOBAL DENGUE TREATMENT MARKET, BY GENDER

12.1 OVERVIEW

12.2 MALE

12.3 FEMALE

13 GLOBAL DENGUE TREATMENT MARKET, BY AGE

13.1 OVERVIEW

13.2 ADULT

13.3 PEDIATRIC

13.4 GERIATRIC

14 GLOBAL DENGUE TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITAL

14.3 SPECIALTY CLINICS

14.4 HOME HEALTHCARE

14.5 OTHERS

15 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 RETAIL PHARMACIES

15.3 HOSPITAL PHARMACIES

15.4 ONLINE PHARMACIES

16 GLOBAL DENGUE TREATMENT MARKET, BY REGION

16.1 OVERVIEW

16.2 ASIA-PACIFIC

16.2.1 INDIA

16.2.2 CHINA

16.2.3 JAPAN

16.2.4 INDONESIA

16.2.5 MALAYSIA

16.2.6 THAILAND

16.2.7 AUSTRALIA

16.2.8 SOUTH KOREA

16.2.9 SINGAPORE

16.2.10 PHILIPPINES

16.2.11 REST OF ASIA-PACIFIC

16.3 SOUTH AMERICA

16.3.1 BRAZIL

16.3.2 ARGENTINA

16.3.3 REST OF SOUTH AMERICA

16.4 NORTH AMERICA

16.4.1 MEXICO

16.4.2 U.S.

16.4.3 CANADA

16.5 EUROPE

16.5.1 FRANCE

16.5.2 GERMANY

16.5.3 SPAIN

16.5.4 U.K.

16.5.5 BELGIUM

16.5.6 ITALY

16.5.7 NETHERLANDS

16.5.8 RUSSIA

16.5.9 SWITZERLAND

16.5.10 TURKEY

16.5.11 REST OF EUROPE

16.6 MIDDLE EAST AND AFRICA

16.6.1 EGYPT

16.6.2 SAUDI ARABIA

16.6.3 SOUTH AFRICA

16.6.4 U.A.E

16.6.5 ISRAEL

16.6.6 REST OF MIDDLE EAST AND AFRICA

17 GLOBAL DENGUE TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.3 COMPANY SHARE ANALYSIS: EUROPE

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 SANOFI

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 VIATRIS INC.

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 JOHNSON & JOHNSON SERVICES, INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 GSK PLC.

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENTS

19.6 AUROBINDO PHARMA

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.7 BAXTER

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.8 FRESENIUS KABI USA

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENTS

19.9 HIKMA PHARMACEUTICALS

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 PERRIGO COMPANY PLC

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 PFIZER INC.

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENTS

19.12 SUN PHARMACEUTICAL INDUSTRIES LTD

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 TEVA PHARMACEUTICALS USA, INC.

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tabela

TABLE 1 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION

TABLE 2 IMPACT OF DELAY IN APPROVAL PROCESS

TABLE 3 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 13 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 14 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 17 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 18 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 19 GLOBAL MILD TO MODERATE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 20 GLOBAL SEVERE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 21 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 22 GLOBAL PARENTERAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 23 GLOBAL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 24 GLOBAL ORAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 25 GLOBAL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 26 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 27 GLOBAL PRESCRIPTION IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 28 GLOBAL OVER-THE-COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 29 GLOBAL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 30 GLOBAL MALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 GLOBAL FEMALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 32 GLOBAL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 33 GLOBAL ADULT IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 GLOBAL PEDIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 35 GLOBAL GERIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 36 GLOBAL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 37 GLOBAL HOSPITAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 38 GLOBAL SPECIALITY CLINICS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 39 GLOBAL HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 40 GLOBAL OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 41 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 42 GLOBAL RETAIL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 43 GLOBAL HOSPITAL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 44 GLOBAL ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 GLOBAL DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 46 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 47 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 48 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 49 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 50 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 51 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 52 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 53 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 54 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 55 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 56 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 57 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 58 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 59 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 60 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 61 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 62 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 63 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 64 INDIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 65 INDIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 66 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 67 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 68 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 69 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 70 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 71 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 72 INDIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 73 INDIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 74 INDIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 75 INDIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 76 INDIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 77 INDIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 78 INDIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 79 INDIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 80 INDIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 81 CHINA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 82 CHINA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 83 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 84 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 85 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 86 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 87 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 88 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 89 CHINA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 90 CHINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 91 CHINA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 92 CHINA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 93 CHINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 94 CHINA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 95 CHINA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 96 CHINA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 97 CHINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 98 JAPAN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 99 JAPAN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 100 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 101 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 102 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 103 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 104 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 105 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 106 JAPAN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 107 JAPAN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 108 JAPAN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 109 JAPAN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 110 JAPAN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 111 JAPAN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 112 JAPAN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 113 JAPAN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 114 JAPAN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 115 INDONESIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 116 INDONESIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 117 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 118 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 119 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 120 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 121 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 122 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 123 INDONESIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 124 INDONESIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 125 INDONESIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 126 INDONESIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 127 INDONESIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 128 INDONESIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 129 INDONESIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 130 INDONESIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 131 INDONESIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 132 MALAYSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 133 MALAYSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 134 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 135 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 136 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 137 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 138 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 139 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 140 MALAYSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 141 MALAYSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 142 MALAYSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 143 MALAYSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 144 MALAYSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 145 MALAYSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 146 MALAYSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 147 MALAYSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 148 MALAYSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 149 THAILAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 150 THAILAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 151 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 152 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 153 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 154 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 155 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 156 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 157 THAILAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 158 THAILAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 159 THAILAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 160 THAILAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 161 THAILAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 162 THAILAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 163 THAILAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 164 THAILAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 165 THAILAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 166 AUSTRALIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 167 AUSTRALIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 168 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 169 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 170 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 171 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 172 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 173 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 174 AUSTRALIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 175 AUSTRALIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 176 AUSTRALIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 177 AUSTRALIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 178 AUSTRALIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 179 AUSTRALIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 180 AUSTRALIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 181 AUSTRALIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 182 AUSTRALIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 183 SOUTH KOREA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 184 SOUTH KOREA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 185 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 186 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 187 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 188 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 189 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 190 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 191 SOUTH KOREA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 192 SOUTH KOREA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 193 SOUTH KOREA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 194 SOUTH KOREA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 195 SOUTH KOREA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 196 SOUTH KOREA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 197 SOUTH KOREA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 198 SOUTH KOREA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 199 SOUTH KOREA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 200 SINGAPORE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 201 SINGAPORE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 202 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 203 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 204 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 205 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 206 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 207 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 208 SINGAPORE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 209 SINGAPORE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 210 SINGAPORE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 211 SINGAPORE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 212 SINGAPORE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 213 SINGAPORE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 214 SINGAPORE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 215 SINGAPORE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 216 SINGAPORE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 217 PHILIPPINES DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 218 PHILIPPINES DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 219 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 220 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 221 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 222 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 223 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 224 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 225 PHILIPPINES DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 226 PHILIPPINES DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 227 PHILIPPINES PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 228 PHILIPPINES ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 229 PHILIPPINES DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 230 PHILIPPINES DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 231 PHILIPPINES DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 232 PHILIPPINES DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 233 PHILIPPINES DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 234 REST OF ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 235 SOUTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 236 SOUTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 237 SOUTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 238 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 239 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 240 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 241 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 242 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 243 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 244 SOUTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 245 SOUTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 246 SOUTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 247 SOUTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 248 SOUTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 249 SOUTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 250 SOUTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 251 SOUTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 252 SOUTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 253 BRAZIL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 254 BRAZIL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 255 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 256 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 257 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 258 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 259 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 260 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 261 BRAZIL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 262 BRAZIL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 263 BRAZIL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 264 BRAZIL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 265 BRAZIL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 266 BRAZIL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 267 BRAZIL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 268 BRAZIL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 269 BRAZIL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 270 ARGENTINA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 271 ARGENTINA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 272 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 273 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 274 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 275 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 276 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 277 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 278 ARGENTINA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 279 ARGENTINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 280 ARGENTINA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 281 ARGENTINA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 282 ARGENTINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 283 ARGENTINA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 284 ARGENTINA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 285 ARGENTINA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 286 ARGENTINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 287 REST OF SOUTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 288 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 289 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 290 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 291 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 292 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 293 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 294 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 295 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 296 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 297 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 298 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 299 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 300 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 301 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 302 NORTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 303 NORTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 304 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 305 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 306 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 307 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 308 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 309 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 310 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 311 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 312 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 313 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 314 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 315 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 316 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 317 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 318 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 319 MEXICO DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 320 MEXICO DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 321 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 322 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 323 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 324 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 325 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 326 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 327 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 328 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 329 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 330 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 331 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 332 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 333 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 334 U.S. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 335 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 336 U.S. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 337 U.S. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 338 U.S. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 339 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 340 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 341 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 342 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 343 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 344 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 345 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 346 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 347 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 348 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 349 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 350 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 351 CANADA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 352 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 353 CANADA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 354 CANADA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 355 CANADA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 356 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 357 EUROPE DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 358 EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 359 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 360 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 361 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 362 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 363 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 364 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 365 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 366 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 367 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 368 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 369 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 370 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 371 EUROPE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 372 EUROPE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 373 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 374 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 375 FRANCE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 376 FRANCE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 377 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 378 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 379 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 380 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 381 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 382 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 383 FRANCE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 384 FRANCE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 385 FRANCE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 386 FRANCE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 387 FRANCE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 388 FRANCE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 389 FRANCE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 390 FRANCE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 391 FRANCE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 392 GERMANY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 393 GERMANY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 394 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 395 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 396 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 397 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 398 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 399 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 400 GERMANY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 401 GERMANY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 402 GERMANY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 403 GERMANY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 404 GERMANY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 405 GERMANY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 406 GERMANY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 407 GERMANY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 408 GERMANY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 409 SPAIN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 410 SPAIN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 411 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 412 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 413 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 414 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 415 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 416 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 417 SPAIN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 418 SPAIN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 419 SPAIN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 420 SPAIN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 421 SPAIN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 422 SPAIN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 423 SPAIN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 424 SPAIN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 425 SPAIN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 426 U.K. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 427 U.K. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 428 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 429 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 430 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 431 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 432 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 433 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 434 U.K. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 435 U.K. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 436 U.K. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 437 U.K. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 438 U.K. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 439 U.K. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 440 U.K. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 441 U.K. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 442 U.K. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 443 BELGIUM DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 444 BELGIUM DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 445 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 446 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 447 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 448 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 449 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 450 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 451 BELGIUM DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 452 BELGIUM DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 453 BELGIUM PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 454 BELGIUM ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 455 BELGIUM DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 456 BELGIUM DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 457 BELGIUM DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 458 BELGIUM DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 459 BELGIUM DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 460 ITALY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 461 ITALY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 462 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 463 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 464 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 465 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 466 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 467 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 468 ITALY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 469 ITALY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 470 ITALY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 471 ITALY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 472 ITALY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 473 ITALY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 474 ITALY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 475 ITALY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 476 ITALY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 477 NETHERLANDS DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 478 NETHERLANDS DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 479 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 480 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 481 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 482 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 483 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 484 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 485 NETHERLANDS DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 486 NETHERLANDS DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 487 NETHERLANDS PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 488 NETHERLANDS ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 489 NETHERLANDS DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 490 NETHERLANDS DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 491 NETHERLANDS DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 492 NETHERLANDS DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 493 NETHERLANDS DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 494 RUSSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 495 RUSSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 496 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 497 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 498 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 499 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 500 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 501 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 502 RUSSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 503 RUSSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 504 RUSSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 505 RUSSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 506 RUSSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 507 RUSSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 508 RUSSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 509 RUSSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 510 RUSSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 511 SWITZERLAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 512 SWITZERLAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 513 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 514 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 515 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 516 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 517 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 518 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 519 SWITZERLAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 520 SWITZERLAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 521 SWITZERLAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 522 SWITZERLAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 523 SWITZERLAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 524 SWITZERLAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 525 SWITZERLAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 526 SWITZERLAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 527 SWITZERLAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 528 TURKEY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 529 TURKEY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 530 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 531 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 532 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 533 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 534 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 535 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 536 TURKEY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 537 TURKEY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 538 TURKEY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 539 TURKEY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 540 TURKEY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 541 TURKEY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 542 TURKEY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 543 TURKEY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 544 TURKEY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 545 REST OF EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 546 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 547 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 548 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 549 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 550 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 551 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 552 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 553 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 554 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 555 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 556 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 557 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 558 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 559 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 560 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 561 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 562 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 563 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 564 EGYPT DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 565 EGYPT DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 566 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 567 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 568 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 569 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 570 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 571 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 572 EGYPT DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 573 EGYPT DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 574 EGYPT PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 575 EGYPT ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 576 EGYPT DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 577 EGYPT DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 578 EGYPT DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 579 EGYPT DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 580 EGYPT DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 581 SAUDI ARABIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 582 SAUDI ARABIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 583 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 584 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 585 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 586 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 587 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 588 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 589 SAUDI ARABIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 590 SAUDI ARABIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 591 SAUDI ARABIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 592 SAUDI ARABIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 593 SAUDI ARABIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 594 SAUDI ARABIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 595 SAUDI ARABIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 596 SAUDI ARABIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 597 SAUDI ARABIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 598 SOUTH AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 599 SOUTH AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 600 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 601 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 602 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 603 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 604 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 605 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 606 SOUTH AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 607 SOUTH AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 608 SOUTH AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 609 SOUTH AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 610 SOUTH AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 611 SOUTH AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 612 SOUTH AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 613 SOUTH AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 614 SOUTH AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 615 U.A.E DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 616 U.A.E DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 617 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 618 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 619 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 620 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 621 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 622 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 623 U.A.E DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 624 U.A.E DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 625 U.A.E PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 626 U.A.E ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 627 U.A.E DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 628 U.A.E DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 629 U.A.E DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 630 U.A.E DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 631 U.A.E DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 632 ISRAEL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 633 ISRAEL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 634 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 635 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 636 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 637 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 638 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 639 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 640 ISRAEL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 641 ISRAEL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 642 ISRAEL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 643 ISRAEL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 644 ISRAEL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 645 ISRAEL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 646 ISRAEL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 647 ISRAEL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 648 ISRAEL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 649 REST OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

Lista de Figura

FIGURE 1 GLOBAL DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL DENGUE TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL DENGUE TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL DENGUE TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL DENGUE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 11 GROWING PHARMACEUTICAL INDUSTRY IS DRIVING THE GROWTH OF THE GLOBAL DENGUE TREATMENT MARKET FROM 2024 TO 2031

FIGURE 12 ON THE BASIS OF STRAINS, THE DENV-2 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DENGUE TREATMENT MARKET IN 2024 AND 2031

FIGURE 13 ASIA-PACIFIC IS EXPECTED TO DOMINATE THE GLOBAL DENGUE TREATMENT MARKET AND EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR GLOBAL DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL DENGUE TREATMENT MARKET

FIGURE 16 FINANCIAL BUDGET FOR VECTOR-BORNE -DISEASES INCLUDING DENGUE IN INDIA

FIGURE 17 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, 2023

FIGURE 18 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, 2024-2031 (USD MILLION)

FIGURE 19 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2024-2031)

FIGURE 20 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE

FIGURE 21 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, 2023

FIGURE 22 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)

FIGURE 23 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 24 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, 2023

FIGURE 26 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, 2024-2031 (USD MILLION)

FIGURE 27 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2024-2031)

FIGURE 28 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE

FIGURE 29 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 30 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)

FIGURE 31 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 32 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 33 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2023

FIGURE 34 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)

FIGURE 35 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)

FIGURE 36 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 37 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, 2023

FIGURE 38 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)

FIGURE 39 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 40 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 41 GLOBAL DENGUE TREATMENT MARKET: BY AGE, 2023

FIGURE 42 GLOBAL DENGUE TREATMENT MARKET: BY AGE, 2024-2031 (USD MILLION)

FIGURE 43 GLOBAL DENGUE TREATMENT MARKET: BY AGE, CAGR (2024-2031)

FIGURE 44 GLOBAL DENGUE TREATMENT MARKET: BY AGE, LIFELINE CURVE

FIGURE 45 GLOBAL DENGUE TREATMENT MARKET: BY END USER, 2023

FIGURE 46 GLOBAL DENGUE TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 47 GLOBAL DENGUE TREATMENT MARKET: BY END USER, CAGR (2024-2031)

FIGURE 48 GLOBAL DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 49 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 50 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 51 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 52 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 53 GLOBAL DENGUE TREATMENT MARKET: SNAPSHOT (2023)

FIGURE 54 GLOBAL DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 55 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 56 EUROPE DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 57 AISA-PACIFIC DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The Dengue Treatment Market Size will reach USD 878.54 million by 2031.
The major companies in the Dengue Treatment Market are Sanofi, Takeda Pharmaceutical Company Limited, Viatris Inc., Johnson & Johnson Services, Inc., GSK plc., Perrigo Company PLC, Baxter, Fresenius Kabi USA, Pfizer, Hikma Pharmaceuticals Plc, SUN PHARMACEUTICAL INDUSTRIES LTD, Teva Pharmaceuticals USA, Inc., and Aurobindo Pharma, Etc.
The Growth Rate of the Dengue Treatment Market will be 11.6% by 2031
The Rising Dengue Incidence Rate Results in the Demand for Effective Treatment & Rising Wave of Dengue Vaccine Launches are the growth drivers of the Tag Management System Market.
The strains, type, severity, route of administration, mode of purchase, gender, age, end user, and distribution channel are the factors on which the Dengue Treatment Market research is based.